Latest News about RDY
Recent news which mentions RDY
Earnings Scheduled For May 12, 2026
May 12, 2026
From Benzinga
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug
June 05, 2025
From Benzinga
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
April 09, 2025
From Benzinga
Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business
January 23, 2025
From Benzinga
Earnings Scheduled For January 23, 2025
January 23, 2025
From Benzinga
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices
January 06, 2025
From Benzinga
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
December 22, 2024
From Benzinga
From Benzinga
Tickers
RDY
From InvestorPlace
Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand
February 22, 2024
From Benzinga
Top 5 Health Care Stocks That May Fall Off A Cliff
August 23, 2023
From Benzinga
Why Are Journey Medical Shares Trading Lower Today?
July 11, 2023
From Benzinga
Why Are Journey Medical Shares Trading Higher Today
June 13, 2023
From Benzinga
The 3 Most Undervalued Value Stocks to Buy in June 2023
June 04, 2023
From InvestorPlace
Why Aditxt Shares Are Surging Today
April 20, 2023
From Benzinga
From Benzinga
From Benzinga
Dr. Reddy's Seeks Gaining Foothold In Women's Health Via Mayne Pharma's U.S. Generic Prescription Deal
February 27, 2023
From Benzinga
The 3 Most Undervalued Stocks in India for Your February Buy List
January 31, 2023
From InvestorPlace
Journey Medical Touts Positive PK Data For Bacterial Infection Candidate
December 20, 2022
From Benzinga
Novartis Fails To Prevent Generic Competition For Its Blockbuster Multiple Sclerosis Drug
October 14, 2022
From Benzinga
Intercept Settles Ocaliva Litigation With Reddy's Lab
August 17, 2022
From Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
August 05, 2022
From Benzinga
From Benzinga
From InvestorPlace
From Benzinga